Reversibility of hepatic fibrosis in treated genetic hemochromatosis: A study of 36 cases
Open Access
- 26 July 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 44 (2), 472-477
- https://doi.org/10.1002/hep.21260
Abstract
The current study was undertaken to assess whether fibrosis could regress under venesection therapy in patients with C282Y homozygous genetic hemochromatosis. The 36 patients studied were recruited from a subfile of our database consisting of 125 C282Y homozygotes with either severe fibrosis or cirrhosis (F3 or F4 fibrosis stage, respectively, according to the METAVIR grading system). The second liver biopsy was performed for management of liver cancer, extrahepatic surgery, or assessment of liver fibrosis. All paired biopsies were reviewed by two pathologists without knowledge of clinical data. Among the 13 patients who had F3 fibrosis on their initial liver biopsy, 3 had F0, 6 had F1, and 2 had F2 on their second liver biopsy. Among the 23 patients with cirrhosis on their initial liver biopsy, 1 had F0, 4 had F1, 3 had F2, and 2 had F3 on their second liver biopsy. When defining regression of fibrosis as a decrease of at least 2 METAVIR units, fibrosis regressed in 9 of 13 (69%) F3 and in 8 of 23 (35%) F4. When the ratio of gammaglobulins (g/L) to (platelets [n/mm3] × prothrombin activity [%]) was greater than 7.5, fibrosis never regressed. In conclusion, these data extend the concept of regression of fibrosis to patients with treated genetic hemochromatosis and suggest that some simple biochemical tests would be predictive of further regression of fibrosis as a result of venesection therapy. If confirmed on larger series, this could modify the ultrasound screening policy of hepatocellular carcinoma in genetic hemochromatosis. (HEPATOLOGY 2006;44:472–477.)This publication has 41 references indexed in Scilit:
- Reversibility of cirrhosis in chronic hepatitis BClinical Gastroenterology and Hepatology, 2004
- Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohortHepatology, 2001
- Regression of Liver Fibrosis after Biliary Drainage in Patients with Chronic Pancreatitis and Stenosis of the Common Bile DuctThe New England Journal of Medicine, 2001
- Resolution of chronic delta hepatitis after 12 years of interferon alfa therapyGastroenterology, 1999
- A One-Year Trial of Lamivudine for Chronic Hepatitis BThe New England Journal of Medicine, 1998
- Sustained Biochemical and Histologic Remission of Primary Biliary Cirrhosis in Response to Medical TreatmentAnnals of Internal Medicine, 1997
- Long-term survival in patients with hereditary hemochromatosisGastroenterology, 1996
- Reversibility of secondary biliary fibrosis by biliodigestive anastomosis in the ratGastroenterology, 1992
- Histological improvement after anti-viral treatment for chronic hepatitis B virus infectionJournal of Hepatology, 1989
- The Reversal of Hemochromatotic Cirrhosis by Multiple PhlebotomiesGastroenterology, 1965